Dj Officer Qatanani Sells 136462 Of Scholar Rock Holding Corp >Srrk

Reuters

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Dj Officer Qatanani Registers 149574 Of Scholar Rock Holding Corp >Srrk

Reuters

Scholar Rock

+0.84%

Risk Warnings and Disclaimers

Add to Favorites

SRRK: Positive Phase 3 results and regulatory delays set the stage for a 2026 U.S. launch of apitegromab

Quartr

Scholar Rock

+0.84%

Significant transformation in 2025 included positive Phase 3 results for apitegromab in SMA, a BLA filing, and leadership changes. Regulatory delays due to manufacturing issues shifted the anticipated U.S. launch to 2026, allowing more time for commercial preparation and global expansion.

Based on Scholar Rock Holding Corporation [SRRK] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 4 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

SRRK: Positive Phase 3 data and regulatory delays set up a 2026 U.S. launch for Apitegromab in SMA

Quartr

Scholar Rock

+0.84%

Significant transformation in 2025 included positive Phase 3 results for Apitegromab in SMA, a BLA filing, and leadership changes. Regulatory delays due to manufacturing issues shifted the expected U.S. launch to 2026, allowing more time for commercial readiness and payer engagement.

Based on Scholar Rock Holding Corporation [SRRK] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 4 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

SRRK: Apitegromab set for 2026 launch as first muscle-targeted SMA therapy, pending manufacturing resolution

Quartr

Scholar Rock

+0.84%

Apitegromab is poised to become the first muscle-targeted therapy for SMA, with strong phase III data supporting its use alongside existing SMN therapies. Regulatory approval is delayed due to manufacturing issues, but launch is expected in 2026, supported by a robust financial position and plans for global expansion.

Based on Scholar Rock Holding Corporation [SRRK] Citi Annual Global Healthcare Conference 2025 Audio Transcript — Dec. 3 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

SRRK: Apitegromab set for 2026 U.S. launch as the first muscle-targeted SMA therapy, with global growth plans

Quartr

Scholar Rock

+0.84%

A world-class leadership team is driving global expansion, with apitegromab positioned as the first muscle-targeted SMA therapy. Regulatory approval is delayed due to manufacturing issues, but financial resources are strong, and a 2026 U.S. launch is targeted.

Based on Scholar Rock Holding Corporation [SRRK] Citi Annual Global Healthcare Conference 2025 Audio Transcript — Dec. 3 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

Scholar Rock Holding Corp - Anticipates Resubmission Of Bla For Apitegromab Launch In 2026 - Sec Filing

Reuters

Scholar Rock

+0.84%

Risk Warnings and Disclaimers

Add to Favorites

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

Dj Officer Qatanani Sells 136462 Of Scholar Rock Holding Corp >Srrk

Dj Officer Qatanani Registers 149574 Of Scholar Rock Holding Corp >Srrk

SRRK: Positive Phase 3 results and regulatory delays set the stage for a 2026 U.S. launch of apitegromab

SRRK: Positive Phase 3 data and regulatory delays set up a 2026 U.S. launch for Apitegromab in SMA

SRRK: Apitegromab set for 2026 launch as first muscle-targeted SMA therapy, pending manufacturing resolution

SRRK: Apitegromab set for 2026 U.S. launch as the first muscle-targeted SMA therapy, with global growth plans

Scholar Rock Holding Corp - Anticipates Resubmission Of Bla For Apitegromab Launch In 2026 - Sec Filing

Risk Disclosure